Polatuzumab vedotin-piiq (ADC)
Polatuzumab vedotin (Polivy) is an ADC consisting of a CD79b-directed antibody and Monomethyl auristatin E (MMAE) that can be used in combination with bendamustine and rituximab for the treatment of adult patients with at least two relapses or refractory diffuse large B-cell lymphoma. Polatuzumab vedotin binds to CD79b and is internalized by tumor cells. MMAE is cleaved from cells by lysosomal protease and promotes tumor cell apoptosis by inhibiting microtubule formation.
Product Specifications
Product Name Alternative
Polivy
Reactivity
Human
Applications
Research Grade Biosimilar
Stability
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks) . Store at -20°C 12 months. Store at -80°C long term.
Endotoxin
Please contact with the lab for this information.
Purity
>90% as determined by SEC.
Form
Liquid
Notes
For research use only. Not suitable for clinical or therapeutic use.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC680012-100 1x 100 µL
Tyrosinase (T311), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470177-500 1x 500 µL
CD50 (ICAM-3) (101-1D2), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880009-100 1x 100 µL
MART-1 / Melan-A (M2-7C10), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680040-500 1x 500 µL
CD35 / CR1 (E11), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC041429-500 1x 500 µL
E-Cadherin / CD324 (Intercellular Junction Marker) (4A2), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details